Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
Capstan Therapeutics, a University of Pennsylvania spinout, is now out of stealth with technology that could enable new medicines that work by engineering cells inside of a patient. Penn biotech pioneers Carl June and Drew Weissman are among the scientific co-founders of this startup, which aims to develop therapies for fibrosis, cancer, inflammation, and genetic diseases.
This on-demand webinar will offer insights and share tips on helping practices run more efficiently.
At $475,000, the therapy isn't cheap but for its part, Novartis has said patients would only pay the full whack if they respond to the therapy by the end of the first month.